Back to top
more

Aclaris Therapeutics (ACRS)

(Real Time Quote from BATS)

$1.25 USD

1.25
127,340

+0.02 (1.63%)

Updated Apr 18, 2024 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aclaris Therapeutics, Inc. [ACRS]

Reports for Purchase

Showing records 1 - 20 ( 28 total )

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

03/04/2024

Company Report

Pages: 5

Balance Sheet Strength; 2023 Financial Results; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

01/22/2024

Company Report

Pages: 5

ATI-1777 Trial Data Disappoints; Strategic Reset; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

12/29/2023

Company Report

Pages: 5

Corporate Update Announced; Headcount Reduction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

12/08/2023

Company Report

Pages: 5

Patent License Agreement Inked With Sun Pharma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

11/14/2023

Company Report

Pages: 5

Zunsemetinib Misses Mark in Rheumatoid Arthritis; Lowering PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

11/13/2023

Company Report

Pages: 5

Data Catalysts Imminent; 3Q23 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

10/04/2023

Company Report

Pages: 5

ATI-1777 Phase 2b Atopic Dermatitis Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

09/19/2023

Company Report

Pages: 5

ATI-2138 Phase 1 Trial Reports Positive Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

08/08/2023

Company Report

Pages: 5

Zunsemetinib Clinical Data Approaching; 2Q23 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

06/14/2023

Company Report

Pages: 5

Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

05/10/2023

Company Report

Pages: 5

Clinical Data Timelines Clarified; 1Q23 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

03/13/2023

Industry Report

Pages: 5

KOL Call Invite: Getting Under the Skin in HS & PsA

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

03/07/2023

Company Report

Pages: 5

Zunsemetinib Misses Mark in Hidradenitis Suppurativa; Lowering PT to $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

02/24/2023

Company Report

Pages: 5

Hidradenitis Suppurativa Data Next Month; 2022 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

12/01/2022

Company Report

Pages: 5

ATI-1777 China License; 3Q22 Financials; Leadership Changes; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

08/08/2022

Company Report

Pages: 5

Clinical Pipeline Continues to Advance; 2Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

05/20/2022

Company Report

Pages: 5

Pipeline Progress Acceleration; 1Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: POLLARD N

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

03/07/2022

Company Report

Pages: 5

Clinical Programs Advancing Apace; 2021 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Aclaris Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

12/20/2021

Company Report

Pages: 5

Zunsemetinib Mid-Stage Trial Details; Portfolio Expansion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party